Poseida Therapeutics, Inc.

This early-stage study is testing a new type of cell therapy called P-CD19CD20-ALLO1 for people with certain B-cell cancers (like diffuse large B-cell lymphoma) that have come back or not responded to standard treatments. The therapy uses donor immune cells that are specially des…

This long-term follow-up study tracks about 100 people with multiple myeloma who previously received the experimental cell therapy P-BCMA-101. The goal is to check for delayed side effects and see how well the treatment controls the cancer over up to 15 years. Participants are mo…

This early-stage study tests a new treatment called P-BCMA-ALLO1 for people with multiple myeloma that has come back or stopped responding to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) from a healthy donor to attack cancer cells. The ma…

This early-phase study tests an experimental cell therapy called P-MUC1C-ALLO1 in 180 adults with advanced solid tumors (e.g., breast, ovarian, lung, pancreatic cancers) that have not responded to standard treatments. The therapy uses donor immune cells engineered to target a pro…